BUSINESS
GSK
BUSINESS
GSK switches CEO as Trump tariffs test pharma
BUSINESS
Britain’s GSK vows US$30bil investment in US as Trump visits
BUSINESS
GSK expects sales and profit at top end of forecast range after Q2 beat
BUSINESS
Malaysia approves GSK’s Arexvy vaccine for RSV
BUSINESS
GSK shares fall after sales of top two vaccines disappoint
BUSINESS
GSK shares tumble 9% after 70,000 Zantac cases allowed to proceed
BUSINESS
GSK lifts outlook again after strong sales of new RSV shot
BUSINESS
Pfizer, GSK’s new RSV vaccines on track for US$2bil in sales
BUSINESS
GSK sues Pfizer over patents for RSV vaccine
BUSINESS
GSK sues Pfizer in US federal court over RSV vaccine
BUSINESS
GSK lifts 2023 forecast on vaccine, HIV drug sales
WORLD
EU approves 1st vaccine for common respiratory virus RSV
BUSINESS
GSK says EU drugs overhaul could trigger investment shift
BUSINESS
GSK to stop selling blood cancer drug Blenrep in US
BUSINESS
Drugmaker GSK’s profit rockets on consumer health spinoff
BUSINESS
GSK buys US cancer firm for US$1.9 bil
WORLD
GSK-Vir therapy neutralises Omicron sub-variant
BUSINESS
GSK expects less profit despite £1.4 bil Covid sales
BUSINESS
Unilever still keen on health unit after bid rebuffed
WORLD
US secures 600,000 more doses of GSK-Vir’s Covid-19 therapy
WORLD
New data shows GSK-Vir drug works against all Omicron mutations
WORLD
Washington bags US$1 bil worth of GSK-Vir antibodies
BUSINESS